Natalia Gasilova
Overview
Explore the profile of Natalia Gasilova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lyutvinskiy Y, Nagornov K, Kozhinov A, Gasilova N, Menin L, Meng Z, et al.
J Am Soc Mass Spectrom
. 2024 Apr;
35(5):902-911.
PMID: 38609335
Traditionally, mass spectrometry (MS) output is the ion abundance plotted versus the ionic mass-to-charge ratio /. While employing only commercially available equipment, Charge Determination Analysis (CHARDA) adds a third dimension...
2.
Site-selective template-directed synthesis of antibody Fc conjugates with concomitant ligand release
Postupalenko V, Marx L, Pantin M, Viertl D, Gsponer N, Giudice G, et al.
Chem Sci
. 2024 Jan;
15(4):1324-1337.
PMID: 38274063
Template-directed methods are emerging as some of the most effective means to conjugate payloads at selective sites of monoclonal antibodies (mAbs). We have previously reported a method based on an...
3.
Fornelli L, Ayoub D, Srzentic K, Nagornov K, Kozhinov A, Gasilova N, et al.
Chimia (Aarau)
. 2023 Dec;
76(1-2):114-126.
PMID: 38069757
Monoclonal antibodies (mAbs) are protein biotherapeutics with a proven efficacy toward fighting life-threatening diseases. Their exceptional healing potential drives the annual increase in the number of novel mAbs and other...
4.
El Samarji M, Younes M, El Khoury M, Haykal T, Elias N, Gasilova N, et al.
Plants (Basel)
. 2023 Feb;
12(3).
PMID: 36771614
Background: belongs to the Amaryllidaceae family and is recognized for the valuable biological activity of its major bioactive compounds. The aim of the current is to evaluate the anticancer effects...
5.
Declas N, Maynard J, Menin L, Gasilova N, Gotze S, Sprague J, et al.
Chem Sci
. 2023 Jan;
14(2):393-394.
PMID: 36687350
[This corrects the article DOI: 10.1039/D2SC04558C.].
6.
Declas N, Maynard J, Menin L, Gasilova N, Gotze S, Sprague J, et al.
Chem Sci
. 2022 Dec;
13(43):12808-12817.
PMID: 36519034
Hypervalent iodine reagents have recently emerged as powerful tools for late-stage peptide and protein functionalization. Herein we report a tyrosine bioconjugation methodology for the introduction of hypervalent iodine onto biomolecules...
7.
Koolen C, Torrent L, Agarwal A, Meili-Borovinskaya O, Gasilova N, Li M, et al.
ACS Nano
. 2022 Jul;
16(8):11968-11978.
PMID: 35876240
Nanoparticles (NPs) have wide applications in physical and chemical processes, and their individual properties (e.g., shape, size, and composition) and ensemble properties (e.g., distribution and homogeneity) can significantly affect the...
8.
Nagornov K, Kozhinov A, Gasilova N, Menin L, Tsybin Y
J Am Soc Mass Spectrom
. 2022 May;
33(7):1113-1125.
PMID: 35638743
The time-domain transients in the Fourier transform mass spectrometry (FTMS) analysis of monoclonal antibodies (mAbs) are known to exhibit characteristic isotopic beat patterns. These patterns are defined by the isotopic...
9.
Postupalenko V, Marx L, Viertl D, Gsponer N, Gasilova N, Denoel T, et al.
Chem Sci
. 2022 Apr;
13(14):3965-3976.
PMID: 35440989
Antibodies are an attractive therapeutic modality for cancer treatment as they allow the increase of the treatment response rate and avoid the severe side effects of chemotherapy. Notwithstanding the strong...
10.
Nagornov K, Gasilova N, Kozhinov A, Virta P, Holm P, Menin L, et al.
Anal Chem
. 2021 Sep;
93(38):12930-12937.
PMID: 34519496
The therapeutic efficacy and pharmacokinetics of antibody-drug conjugates (ADCs) in general, and antibody-oligonucleotide conjugates (AOCs) in particular, depend on the drug-to-antibody ratio (DAR) distribution and average value. The DAR is...